Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Very Bullish +85

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength

AI-generated analysis

πŸ“ˆ Regeneron reported Q1 2026 adjusted EPS of $9.47, exceeding analyst estimates and rising from the prior year quarter.

πŸ’° Total revenues reached $3.6 billion, a 19% increase driven by Dupixent and Eylea HD performance.

πŸ“‰ Stock price dropped 5.2% year-to-date despite earnings beat due to a year-over-year decline in GAAP earnings.

πŸ’Š Dupixent collaboration revenue with Sanofi rose 36% to $1.6 billion, fueled by 33% growth in global Dupixent sales to $4.9 billion.

πŸ‘οΈ Eylea HD revenues jumped 52% to $468 million in the U.S., supported by higher doses and volume demand.

⚠️ Legacy Eylea brand sales fell 36% year-over-year to $473 million as patients transitioned to the higher-dose formulation.

🀝 Collaboration revenues totaled $1.9 billion, up 24%, with Bayer's contribution down to $287 million while Sanofi paid increased royalties on Praluent and Libtayo.

πŸ’‰ Praluent sales in the U.S. reached $67 million, while Libtayo global net sales surged 54% to $438 million.

πŸ“Š Gross margin improved slightly to 86%, while adjusted R&D expenses grew 19% to $1.4 billion for pipeline advancement.

πŸ”„ Share repurchases totaled $803 million in Q1, with a new authorization allowing an additional $3.0 billion in buybacks.

βœ… FDA approved Dupixent for chronic spontaneous urticaria in children aged two to 11, expanding the pediatric indication.

πŸ’‰ FDA granted approval for extending Eylea HD dosing intervals up to 20 weeks for certain patients after sustained response.

⚠️ Regeneron faces a regulatory decision delay on a second pre-filled syringe manufacturing application at Catalent's Indiana site following re-inspection.

Bullish Signals
  • Regeneron reported first-quarter 2026 adjusted earnings per share (EPS) of $9.47, comfortably beating the Zacks Consensus Estimate of $8.52.
  • Total revenues grew 19% year over year to $3.6 billion, driven by strong sales performance from Eylea HD and increased Dupixent profits.
  • Eylea HD generated revenues of $468 million in the United States, representing a significant 52% year-over-year increase.
  • Dupixent sales increased 33% year over year to $4.9 billion, with Sanofi collaboration revenues increasing 36% to $1.6 billion.
  • Libtayo sales totaled $438 million, up 54% year over year, and beat the Zacks Consensus Estimate of $361 million.
  • Regeneron repurchased $803 million worth of common stock during the first quarter of 2026, with $688 million remaining available for buybacks.
  • The company's gross margin improved to 86% from 85% on net product sales, reflecting operational efficiency.
  • In April 2026, the FDA and European Commission approved Dupixent for chronic spontaneous urticaria in children aged two to 11 years, expanding its market reach.
  • The FDA also approved extending Eylea HD dosing intervals up to 20 weeks for wAMD and DME patients, enhancing treatment flexibility.
Risk Factors
  • Despite strong earnings, Regeneron's shares have lost 5.2% so far this year compared to the industry's decline of only 1.5%, indicating underperformance relative to peers.
  • Eylea sales in the United States plunged 36% year over year to $473 million due to increased competition from Roche's RHHBY Vabysmo and patient transitions to higher doses of Eylea HD.
  • Sales were negatively impacted by lower wholesaler inventory levels at the end of the first quarter of 2026 compared to the fourth quarter of 2025.
  • Bayer's collaboration revenues totaled $287 million, down 17% year over year, showing declining revenue from a key partner despite overall business growth.
  • A decision on a second PFS manufacturing application for Eylea HD was not made by the April 2026 target date following re-inspection concerns at Catalent's Indiana site.
  • Adjusted SG&A expenses increased 4% to $560 million due to higher commercialization costs and headcount expenses, potentially impacting future profit margins if revenue growth slows.
  • Operating leverage may face pressure as Eylea HD sales, while growing, still require managing inventory and competition risks that limit top-line expansion in a key therapeutic area.
Full Analysis
Regeneron Pharmaceuticals reported first-quarter 2026 adjusted earnings per share of $9.47, surpassing the Zacks Consensus Estimate of $8.52 and rising from $8.22 in the year-ago quarter. Total revenues increased 19% year over year to $3.6 billion, driven by higher sales of Eylea HD and expanded Dupixent profits, exceeding the consensus estimate of $3.4 billion. Despite this bottom-line strength, Regeneron's shares have declined 5.2% so far this year compared with the broader industry's 1.5% drop, as GAAP earnings decreased year over year. The company also repurchased $803 million worth of common stock in Q1 and holds approximately $688 million under its share repurchase programs, with a new authorization for up to $3.0 billion in additional buybacks planned for April 2026. Revenue growth was primarily fueled by collaboration revenues totaling $1.9 billion, a 24% increase from the prior quarter, which included $1.6 billion from Sanofi associated with Dupixent and $287 million from Bayer linked to Eylea. Dupixent global net product sales rose 33% year over year to $4.9 billion due to higher profits in the collaboration arrangement. The lead ophthalmology drug, Eylea HD, generated $468 million in U.S. sales, up 52%, driven by increased demand and FDA approval for extended dosing intervals of up to 20 weeks for wet age-related macular degeneration and diabetic macular edema patients. While U.S. Eylea original drug sales fell 36% due to competition from Roche’s Vabysmo and patient transitions, the Eylea HD launch helped offset this decline, beating the consensus estimate by 0.12%. Other product lines also contributed to the financial performance, with Libtayo U.S. and global net sales reaching $438 million, a 54% year-over-year increase that exceeded expectations of $361 million, while Praluent recorded $67 million in net sales in the United States. Gross margin on net product sales improved slightly to 86% from 85%. Operating expenses saw Adjusted R&D costs rise 19% year over year to $1.4 billion due to pipeline advancements in hematology-oncology and complement-mediated diseases, while Adjusted SG&A expenses grew 4% to $560 million owing to commercialization efforts for Eylea HD and Libtayo. Regulatory developments included FDA approvals for Dupixent treating chronic spontaneous urticaria in children aged two to 11 and allergic fungal rhinosinusitis in patients six and older, with additional manufacturing applications for Eylea HD syringes under review at Catalent's Indiana site.